Adaptive Biotechnologies (ADPT) Earnings: Q3 2026 Results and Next Report Date

The quarter ended September 30, 2026 and Adaptive Biotechnologies published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• The Genentech Agreement was terminated on August 13, 2025, effective February 9, 2026. It contributed $33.7 million of Immune Medicine revenue in Q3 2025 and none in Q3 2026, which is why total revenue fell while MRD revenue grew.
• In June 2026 Adaptive Biotechnologies announced plans to separate its MRD and Immune Medicine businesses; the separation remains ongoing.

Source: Adaptive Biotechnologies Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Adaptive Biotechnologies splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Adaptive Biotechnologies's MRD revenue was $72.6 million in Q3 2026, up 28% from $56.8 million in Q3 2025, 86% of total revenue.
• Adaptive Biotechnologies's Immune Medicine revenue was $11.3 million in Q3 2026, down 70% from $37.2 million in Q3 2025, 14% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Adaptive Biotechnologies said:

“Adaptive Biotechnologies expects full year revenue for the MRD business to be between $276 million and $286 million, updated from the previous range between $268 million and $278 million.”

“No revenue guidance is provided for the Immune Medicine business.”

“We expect full year total company operating expenses, including cost of revenue, to be approximately $350 million, updated from the previous range between $350 million and $355 million.”

Source: Adaptive Biotechnologies Q3 2026 release, Nov 4, 2026.

This is the company's own guidance as of Nov 4, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the ADPT forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and basic and diluted EPS attributable to Adaptive Biotechnologies, each as first reported in that quarter's release. Q2 2026 includes a $23.7 million loss on extinguishing the revenue interest liability.

Adaptive Biotechnologies's next report is expected around February 4, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q3 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Adaptive Biotechnologies reported Q3 2026 revenue of $83.9 million, down 11% from $94.0 million, because the year-ago quarter included $33.7 million of collaboration revenue from Genentech and this quarter had none. Excluding the Genentech Agreement, revenue rose 39%. (Adaptive Biotechnologies Q3 2026 release, Nov 4, 2026; Adaptive Biotechnologies Form 10-Q, Q3 2026, Nov 4, 2026)

MRD, the minimal residual disease business built on the clonoSEQ test, brought in $72.6 million, up 28%, or 44% excluding milestones. All of it was service revenue; a year earlier MRD included $6.5 million of regulatory milestone revenue. Adaptive attributed the $15.8 million increase to a $17.8 million rise in clonoSEQ revenue from clinical customers and a $6.5 million rise in MRD testing for biopharmaceutical customers, offset by $6.5 million lower milestone revenue and $2.2 million less from investigator-led trials. (Adaptive Biotechnologies Q3 2026 release, Nov 4, 2026; Adaptive Biotechnologies Form 10-Q, Q3 2026, Nov 4, 2026)

clonoSEQ volume rose 46% to 39,587 tests from 27,111. For Medicare patients Adaptive bills one episode of treatment at the first eligible test, currently estimated at about four tests per patient, and recognizes revenue as tests are delivered. In Q3 2026 it recognized $3.2 million of MRD revenue from Medicare reimbursements where further testing for specific patients became remote, against $2.9 million a year earlier. (Adaptive Biotechnologies Form 10-Q, Q3 2026, Nov 4, 2026)

Immune Medicine revenue was $11.3 million, down 70%, but up 229% excluding Genentech. The 10-Q credits a $9.0 million increase from its target discovery agreement, offset by $1.1 million less from immunosequencing services, which Adaptive decided in July 2026 to wind down. Adaptive gives no revenue guidance for Immune Medicine and expects that revenue to decrease in the short term. (Adaptive Biotechnologies Q3 2026 release, Nov 4, 2026; Adaptive Biotechnologies Form 10-Q, Q3 2026, Nov 4, 2026)

Adaptive Biotechnologies earned $0.02 per share in Q3 2026, against $0.06 a year earlier, on net income attributable to Adaptive of $2.9 million against $9.5 million. The year-ago profit rested on the Genentech revenue: excluding it, Adaptive says Q3 2025 would have been a $24.2 million net loss. Diluted weighted average shares were 186,879,656, against 163,162,107, and basic shares 160,400,525. (Adaptive Biotechnologies Q3 2026 release, Nov 4, 2026)

Adaptive does not report an adjusted EPS. Its adjusted EBITDA was $14.3 million, against $28.0 million, and excludes share-based compensation ($10.4 million), depreciation and amortization ($3.6 million), restructuring ($0.7 million) and interest. By segment, MRD adjusted EBITDA was $15.1 million and Immune Medicine $3.2 million. (Adaptive Biotechnologies Q3 2026 release, Nov 4, 2026)

Interest expense fell to $0.5 million from $3.0 million after Adaptive extinguished its revenue interest liability, paying $148.1 million and recording a $23.7 million loss earlier in 2026. On June 22, 2026 it issued $345.0 million of 0% convertible senior notes due 2031. Over the first nine months of 2026 it also paid $25.6 million for capped calls and repurchased 1,451,800 shares for $25.0 million. (Adaptive Biotechnologies Q3 2026 release, Nov 4, 2026; Adaptive Biotechnologies Form 10-Q, Q3 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Adaptive Biotechnologies guides only the MRD business and total operating expenses. With Q3 2026 it raised full-year MRD revenue guidance to $276 million to $286 million, from $268 million to $278 million, which it describes as annual growth of 30% to 35%. It now expects full-year operating expenses, including cost of revenue, of approximately $350 million, from a previous $350 million to $355 million. It gives no Immune Medicine revenue guidance. (Adaptive Biotechnologies Q3 2026 release, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Adaptive Biotechnologies, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Adaptive Biotechnologies's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning ADPT is on is ADPT a buy or a sell?, what analysts expect next is on the ADPT forecast, and what the company does is on the Adaptive Biotechnologies (ADPT) stock page.

Every number on this page can be traced to a document Adaptive Biotechnologies published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.